Objectives: To determine whether migration of pathological tumor stages in patients with clinically localized prostate cancer exists and whether this is due to an increasing frequency of treating patients with clinically insignificant cancer.Methods: 1,063 radical retropubic prostatectomies were performed in patients with clinically localized prostate cancer in one institution within 7.5 years (from 1992 until June 1999). All specimens were prospectively processed according to the Stanford protocol. These were then analyzed regarding the migration of pathological tumor stages and cancer volumes.Results: Within the observation period, the annual rate of radical retropubic prostatectomies increased by 225% from 69 to 224 cases. The authors noted a decline of advanced tumor stages (from 65 to 40%) and an increase in pathological T2 tumors (from 30 to 55%). The rate of small cancers (<0.5 cm3) remained stable between 2 and 5% over the last 5 years.Conclusion: The data confirm trends which were observed in large US centers with increasing detection and treatment of localized prostate cancer without unnecessary treatment of clinically insignificant cancers.

Keywords:
Localized prostate cancer, Stage migration, Prostate–specific antigen, Tumor stage
1.
Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. CA Cancer J Clin 1994;44:7–26.
2.
Polascik TJ, Oesterling JE, Partin AW: Prostate specific antigen: A decade of discovery – what we have learned and where we are going. J Urol 1999;162:293–306.
3.
Mettlin CJ, Murphy GP: Why is the prostate cancer death rate declining in the United States? Cancer 1998;82:249–251.
4.
Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP: Localized prostate cancer. Cancer 1993;71(suppl):933– 938.
5.
Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT: Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997;157:2212–2218.
6.
McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA: Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990;66:1225–1233.
7.
Hermanek P, Sobin LH: TNM Classification, ed 4. Berlin, Springer 1992, pp 141–144.
8.
Walsh PC: Radical retropubic prostatectomy; in Walsh PC, Retik AB, Stamey TA, Vaughan ED (eds): Campell’s Urology, ed 6. Philadelphia, Saunders, 1992, pp 2865–2886.
9.
Mettlin CJ, Murphy GP, Ho R, Menck HR: The National Cancer Data Base Report on longitudinal observations on prostate cancer. Cancer 1996;77:2162–2166.
10.
Mettlin C: Changes in patterns of prostate cancer care in the United States: Results of American College of Surgeons Commission on Cancer Studies. Prostate 1997;323:221–226.
11.
Oesterling JE, Steven JJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM: Serum prostate–specific antigen in a community–based population of healthy men: Establishment of age–specific reference ranges. JAMA 1993;270:860–864.
12.
Stamey TA: Making the most out of six systematic biopsies. Urology 1995;45:2–12.
13.
Stamey TA: Techniques for avoiding positive surgical margins during radical prostatectomy. Atlas Urol Clin North Am 1994;2:37–51.
14.
Ackerman DA, Barry JM, Wicklund RA, Olsen N, Lowe BA: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 1993;150:1845– 1850.
15.
Catalona WJ, Bigg SW: Nerve–sparing radical prostatectomy: Evaluation of results after 250 patients. J Urol 1990;143:538–544.
16.
Epstein JI, Carmichael MJ, Partin AW, Walsh PC: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariante analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow–up. J Urol 1993;149:1478– 1481.
17.
Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152:1843–1849.
18.
Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT: Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992;148:331–337.
19.
Stamey TA, Villers AA, McNeal JE, Link PC, Freiha FS: Positive surgical margins at radical prostatectomy: Importance of the apical dissection. J Urol 1990;143:1166–1173.
20.
Catalona WJ, Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate–term results. J Urol 1998;160: 2428–2434.
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.